Altimmune, Inc. logo

Altimmune, Inc. (ALT)

Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
3. 09
-0.02
-0.6431%
$
622.32M Market Cap
- P/E Ratio
11.64% Div Yield
2.34M Volume
-1.47 Eps
$ 3.11
Previous Close
Add Transaction
Day Range
3.02 3.1
Year Range
2.56 6.44
Want to track ALT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class Action - ALT

Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class Action - ALT

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Accesswire | 2 years ago
IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!

IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

Accesswire | 2 years ago
Class Action Filed Against Altimmune, Inc. (ALT) - July 5, 2024 Deadline to Join - Contact Levi & Korsinsky

Class Action Filed Against Altimmune, Inc. (ALT) - July 5, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit – ALT

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit – ALT

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)

Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit

IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

Accesswire | 2 years ago
Altimmune, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

Altimmune, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 2 years ago
Loading...
Load More